...
首页> 外文期刊>Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis >In vitro synergism between LFA-1 targeting leukotoxin (Leukothera) and standard chemotherapeutic agents in leukemia cells.
【24h】

In vitro synergism between LFA-1 targeting leukotoxin (Leukothera) and standard chemotherapeutic agents in leukemia cells.

机译:白血病细胞中靶向LFA-1的白细胞毒素(Leukothera)与标准化学治疗剂之间的体外协同作用。

获取原文
获取原文并翻译 | 示例

摘要

Leukotoxin (Leukothera; LtxA) is a bacterial protein and experimental therapeutic that binds leukocyte function antigen (LFA-1) on white blood cells (WBCs) and induces cell death via apoptosis or necrosis. We previously found that LtxA preferentially targets WBCs with high levels of activated LFA-1, which is characteristic of many leukemias and lymphomas, and showed that LtxA exhibits significant anti-leukemia activity in vivo using the humanized SCID mouse model. In this report, we demonstrate that LtxA induces very rapid (1h) apoptosis in acute monocytic leukemia THP-1 cells characterized by binding of annexin V to cells, loss of mitochondrial membrane potential, depletion of cellular ATP, and fragmentation of chromosomal DNA. We tested the activity of LtxA in combination with the standard chemotherapeutic agents, etoposide, mitoxantrone, daunorubicin, busulfan, and imatinib against several leukemia cell lines, including THP-1, GDM-1, HL-60, and KU-812 cells. LtxA exhibited synergism with all the drugs, and the levels of synergy were dependent on the doses used and cell lines examined. In general, the greatest level of synergy was observed with LtxA and etoposide or imatinib. Combination index (CI) values were less than 0.1 for many of the combinations, indicating very strong synergism. In addition, LtxA alone was cytotoxic to primary cells from newly diagnosed, relapsed, and refractory patients with different hematological malignancies. Thus, LtxA is highly effective at inducing rapid apoptosis both as a single agent and in combination with approved leukemia therapies.
机译:白细胞毒素(Leukothera; LtxA)是一种细菌蛋白和实验性治疗药物,可与白细胞(WBC)上的白细胞功能抗原(LFA-1)结合并通过凋亡或坏死诱导细胞死亡。我们先前发现LtxA优先靶向具有高水平活化LFA-1的WBC,这是许多白血病和淋巴瘤的特征,并显示了LtxA在人源化SCID小鼠模型中表现出显着的体内抗白血病活性。在此报告中,我们证明LtxA在急性单核细胞白血病THP-1细胞中诱导非常快速的(1h)凋亡,其特征在于膜联蛋白V与细胞结合,线粒体膜电位丧失,细胞ATP耗竭和染色体DNA断裂。我们测试了LtxA与标准化疗药,依托泊苷,米托蒽醌,柔红霉素,白消安和伊马替尼联合使用对几种白血病细胞系(包括THP-1,GDM-1,HL-60和KU-812细胞)的活性。 LtxA表现出与所有药物的协同作用,并且协同作用的水平取决于所用剂量和所检查的细胞系。通常,与LtxA和依托泊苷或伊马替尼的协同作用最大。许多组合的组合指数(CI)值均小于0.1,表明具有很强的协同作用。此外,单独的LtxA对新诊断,复发和难治性血液恶性肿瘤患者的原代细胞具有细胞毒性。因此,LtxA作为单一药物或与批准的白血病疗法联合使用均能有效诱导快速凋亡。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号